Shengnuo Pharmaceutical-B (02257): Phase II clinical trial of STP705 for medical aesthetics completed first patient administration

Zhitongcaijing · 2d ago

Zhitong Finance App News, Shengnuo Pharmaceutical-B (02257) issued an announcement evaluating that the phase II clinical trial of STP705 for medical treatment has successfully completed the first dose to the first study participant. This achievement is a major clinical milestone in the Group's global RNA therapy medical and aesthetic pipeline.

The main end point of this phase II multicenter trial was to systematically evaluate the clinical efficacy of STP705 to achieve targeted subcutaneous fat reduction through topical administration, along with a rigorous secondary evaluation covering safety, tolerability, and local treatment response characteristics.

STP705 relies on the Group's proprietary PNP oligonucleotide delivery platform to enable site-specific gene regulation to drive controlled adipocyte clearance, providing a minimally invasive treatment alternative to traditional fat loss therapies. The clinical readout data from this Phase II project will generate key efficacy data to support the global development trajectory of the Group's medical and aesthetic assets and further strengthen siRNAomics's leading market position in the field of extra-hepatic siRNA delivery models.